Shortcut Navigation:

Breast Cancer News

In this section, access cutting-edge breast cancer news on treatment updates, emerging therapies, study results and other medical and quality-of-life issues important to you.

Company Requests Hearing for Avastin

Roche/Genentech, maker of Avastin (bevacizumab), has requested a hearing before the U.S. Food and Drug Administration to appeal the agency’s December 2010 decision to withdraw approval of bevacizumab as a treatment for metastatic breast cancer.

Avastin raises heart failure risk in breast cancer

CHICAGO (Reuters) - Women with advanced breast cancer who were treated with Roche's Avastin were more likely to develop heart failure than other women, according to an analysis released on Tuesday that raised more concerns about the already troubled drug.

Family history not the sole risk for breast cancer

NEW YORK (Reuters Health) - A new study reconfirms something often forgotten by women and sometimes even by doctors: just because breast cancer has not struck a family before does not mean family members are safe from the disease.

Some soy supplements OK for long-term use

NEW YORK (Reuters Health) - Menopausal women who take a certain type of soy supplement long-term aren't at increased risk for breast cancer or any other ill effects, a new two-year study suggests.

Weight-Lifting Found Safe After Breast Surgery

The PAL Trial, announced at the 2010 San Antonio Breast Cancer Symposium, showed that women whose lymph nodes are removed during breast cancer surgery may safely lift weights of 1 to 2 pounds without increasing their chances for developing lymphedema.

Women Respond to FDA Ruling on Avastin

Women with metastatic breast cancer share how they feel about FDA’s decision to rescind approval of bevacizumab (Avastin) as a treatment for metastatic breast cancer.

FDA Approves Bone Medicine for Use in Bone Metastasis

The Food and Drug Administration (FDA) has approved denosumab to help prevent bone damage in people with cancer that has spread to the bone tissue.

LBBC Medical Advisors React to Avastin Decision

Members of Living Beyond Breast Cancer's Medical Advisory Board react to the FDA decision to withdraw approval of Avastin as a treatment for metastatic breast cancer.

Living Beyond Breast Cancer Statement on FDA’s Decision to Remove Approval of Avastin for Metastatic Breast Cancer

The U.S. Food and Drug Administration (FDA) yesterday announced that it plans to begin the process necessary to withdraw approval of Avastin (bevacizumab) as a treatment for metastatic breast cancer. Living Beyond Breast Cancer (LBBC) encourages insurance carriers and the federal government to continue reimbursing payment for Avastin for women currently taking it who are responding to it. Additionally, we strongly encourage the manufacturer to continue its program to assist women in need who are taking Avastin and are responding.

FDA Rules Against Avastin

FDA's announcement that it plans to withdraw approval of Avastin in metastatic breast cancer begins a review process that could last several months. Learn about the timeline for a decision, the impact on access and insurance coverage, and how to submit public comments to FDA.

Denver, CO  ·  September 13, 2014

Join Your Community for Yoga on the Steps!

Close
close